A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable or neutralizing the virus, antibody levels in serum were higher in hamsters immunized by an intranasal compared to intramuscular route. Accordingly, ChAd-SARS-CoV-2-S immunized hamsters were protected against a challenge with a high dose of SARS-CoV-2. After challenge, ChAd-SARS-CoV-2-S-immunized hamsters had less weight loss and showed reductions in viral RNA and infectious virus titer in both nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 03. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bricker, Traci L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.07.2021 published: Electronic UpdateIn: Cell Rep. 2021 Jun 29;:109400. - PMID 34245672 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.12.02.408823 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318654008 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318654008 | ||
| 003 | DE-627 | ||
| 005 | 20231225165813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.02.408823 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318654008 | ||
| 035 | |a (NLM)33299991 | ||
| 035 | |a (PII)2020.12.02.408823 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bricker, Traci L |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.07.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cell Rep. 2021 Jun 29;:109400. - PMID 34245672 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable or neutralizing the virus, antibody levels in serum were higher in hamsters immunized by an intranasal compared to intramuscular route. Accordingly, ChAd-SARS-CoV-2-S immunized hamsters were protected against a challenge with a high dose of SARS-CoV-2. After challenge, ChAd-SARS-CoV-2-S-immunized hamsters had less weight loss and showed reductions in viral RNA and infectious virus titer in both nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Darling, Tamarand L |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Ahmed O |e verfasserin |4 aut | |
| 700 | 1 | |a Harastani, Houda H |e verfasserin |4 aut | |
| 700 | 1 | |a Soung, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Ya-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Lucas J |e verfasserin |4 aut | |
| 700 | 1 | |a Holtzman, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Adam L |e verfasserin |4 aut | |
| 700 | 1 | |a Case, James Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Fremont, Daved H |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Robyn |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Boon, Adrianus C M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 03. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:03 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.02.408823 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 03 |c 12 | ||